







Health-Related Quality of Life (HRQoL) in COVID-19 Patients After Recovering from the Acute Infection

Dena Firouzabadi ^{1,2}, Laleh Mahmoudi ^{1,3,*}, Maryam Kadkhodamohammadi¹, Ramin Niknam ⁴, Ali Amanati ⁵

¹ Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

² Department of Clinical Pharmacy, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

³ Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

⁴ Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

⁵ Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding Author: Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. Email: mahmoudi_l@sums.ac.ir

Received: 2 June, 2024; Revised: 31 July, 2024; Accepted: 20 August, 2024

Abstract

Background: Nearly four years after the COVID-19 outbreak, its burden persists, with long-term physical and mental impacts still being discovered.

Objectives: Given that these effects may vary across different periods post-infection and in diverse cultural, medical, and economic settings, we aimed to evaluate the health-related quality of life (HRQoL) in Iranian patients six months after acute infection.

Methods: A total of 194 infected patients were enrolled and re-evaluated six months after the onset of acute infection. Health-related quality of life was assessed using the validated EQ-5D-3L questionnaire.

Results: The mean age of patients was 50.1 ± 15.8 years, with a female-to-male ratio of 1.04. Diabetes mellitus and hypertension were the most common comorbidities. Significant impairment was observed in all categories of HRQoL after recovery from acute COVID-19 infection (P -value < 0.05). Female gender, older age, and intensive care unit admissions were independent factors associated with worsened health status post-recovery. The overall reduction in post-COVID-19 infection quality of life (QoL) score was 25%.

Conclusions: The mental and physical burden of COVID-19 in our study population was considerable. Comorbid conditions and a lack of supportive measures post-infection, especially in a low-income country, may contribute to the long-term effects of COVID-19.

Keywords: Mental Health, Pandemic, Physical Health, SARS-CoV-2, Viral Infection

1. Background

The sudden outbreak of a viral infection in December 2019 in Wuhan, China, led to a global tragedy, officially declared a pandemic by the World Health Organization (WHO) in March 2020. The responsible pathogen, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), caused COVID-19 infection. It rapidly spread worldwide, leading to hospitalizations and large numbers of patients requiring intensive care within weeks. Initially, the primary symptoms were nonspecific, such as fever,

cough, dyspnea, muscle pain, and headache, but over time, the spectrum of symptoms expanded (1, 2).

With increasing global life expectancy, quality of life (QoL) has become one of the most important indicators of modern society. The WHO defines quality of life (WHOQoL) as "people's perception of their position in life in the context of the culture and value system in which they live and in relation to their goals, expectations, standards, and concerns" (3). Research on the impact of the COVID-19 pandemic on QoL in several

countries has revealed significant influences on physical, mental, social, and spiritual health (4-7).

In the Iranian population, studies have shown a severe decline in health-related QoL (HRQoL) in the short-term follow-up after COVID-19 infection (8). Female gender and older age (≥ 40 years) were associated with both physical and mental impairments one month after recovery (9). However, the mid- and long-term complications for COVID-19 survivors post-hospital discharge remain less understood. A study in Italy found that, seven weeks after discharge, 53% of patients reported fatigue, 43% had shortness of breath, and 27% experienced persistent joint pain (7). Severe lower respiratory complications, such as pneumonia and acute respiratory distress syndrome (ARDS), were early recognized complications requiring oxygen support or ventilators (10, 11).

The NHS in England has predicted a high burden of physical, neurological, and social needs for COVID-19 survivors, much of which stems from ARDS (12). As the infection spread, more complications involving cardiovascular, renal, and neurological systems emerged. Some were caused by the virus itself, while others were due to long hospital admissions or medications used in COVID-19 treatment. Complications seem to persist long after recovery from the acute phase, with hypoxic damage, neurological sequelae (such as dysgeusia, anosmia, ataxia, convulsions) (13), and impaired respiratory function (14) significantly impairing patients' future QoL.

The pandemic's impact on mental health has been substantial, with anxiety and depression being particularly concerning. Different populations, depending on socioeconomic status and available resources, may experience the pandemic's effects differently.

2. Objectives

This study aims to assess the physical and psychological impairments (levels of anxiety and depression) observed in patients six months after recovery from acute COVID-19, using HRQoL assessments via a validated questionnaire.

3. Methods

This cross-sectional study included patients from emergency departments, infectious wards, and clinics designated for COVID-19 management. Ethics approval

was obtained from the Shiraz University of Medical Sciences (IR.SUMS.REC.1399.1007). Informed consent was collected from all participants.

Inclusion criteria were: Confirmed COVID-19 infection via RT-PCR, candidacy for one of the available treatment modalities (remdesivir, favipiravir, tocilizumab, or pirfenidone), and consent to participate. Patients were interviewed during the acute phase, with demographic data being collected. Six months after their confirmed infection, patients were re-interviewed to assess their QoL post-COVID-19 infection. This assessment was based on the validated Persian version of the EQ-5D-3L questionnaire, which measures health-related quality of life (HRQoL) regardless of the disease (EuroQol. EQ-5D is available upon request from <https://euroqol.org>). Using this questionnaire, five areas were evaluated: Mobility, personal care, usual activities, pain, and anxiety/depression. The questionnaire consisted of three main sections: Demographic information, including gender, age, education level, marital status, and employment status; general health status, where participants were asked about their perceptions of their health and any existing illnesses or health issues using the question, "Do you have any illness, health problem, condition, or disability?" Those who reported any issues were prompted to identify specific conditions from a list or specify their illnesses, with the option to mention multiple conditions; and the EQ-5D-3L assessment, which was used to evaluate the participants' HRQoL score. Each area was graded at three levels: No problems, some problems, and extreme problems. Patients confirmed their health status by marking their current condition, and each section was assigned a score reflecting the level of impairment. The overall assessment was represented by a five-digit number describing the patient's overall health status. EQ-5D-3L items were assessed at both time points, before and after the infection, to allow for a better comparison of HRQoL impairment. At the end of the questionnaire, participants rated their overall QoL post-COVID-19 infection on a scale of 1 - 100, assuming their pre-infection QoL score was 100.

Statistical analysis was conducted using IBM SPSS 28 software. For quantitative data, the mean \pm SD was used, while qualitative data were summarized using medians. Data frequency was expressed as a percentage. The comparison of qualitative parameters in the questionnaire was performed using the chi-square test,

and the overall QoL before and after COVID-19 infection was evaluated with an independent *t*-test. A *P*-value < 0.05 was considered statistically significant. Kruskal-Wallis analysis was employed to evaluate differences between pre- and post-COVID-19 assessments across different categories. Since various factors might interfere with the study outcome, baseline characteristics documented at the beginning of the study were analyzed for their association with patients' HRQoL using a regression analysis model. Factors such as age, gender, education level, history of comorbid diseases, and ICU admission were evaluated for their potential association with impairments in HRQoL in this study population.

4. Results

Out of 651 COVID-19 infected patients initially surveyed for inclusion, 289 potential participants were identified, with 95 subsequently excluded, as shown in the study's flow diagram. Ultimately, 194 patients met the inclusion criteria and were enrolled in this cross-sectional study (Figure 1). The baseline demographic and clinical data of the patients are presented in Table 1. The study population consisted of a nearly equal number of male (95) and female (99) patients, with a mean age of 50.1 ± 15.8 years. The majority of participants had a low level of education, and most had a history of diabetes mellitus and hypertension. While most patients were hospitalized during the course of their infection, the majority did not experience a severe form requiring ICU admission. The average duration of COVID-19 infection with acute symptoms was 28 ± 2.1 days.

The assessment of patients' HRQoL before and after COVID-19 infection, using the EQ-5D-3L questionnaire, is shown in Table 2. Impairment was observed across all fields. In terms of mobility, patients in the post-COVID-19 phase mostly reported difficulty walking compared to their pre-infection ability. Regarding self-care, there was mild impairment, with difficulties in daily activities such as showering or dressing independently. There was slight impairment in usual activities after the infection, while pain and discomfort significantly increased. Mental and psychological effects, particularly anxiety and depression, were also significantly heightened after the infection, with anxiety, depression, and difficulty walking being the most prominent issues.

After evaluating responses in the five categories, significant impairment in all HRQoL categories was observed when comparing pre- and post-COVID-19 scores (*P*-value < 0.05), as presented in Table 3. According to Table 4, older age (≥ 40 years), female gender, and ICU admission were associated with worsened health status post-COVID-19 infection.

The mean overall reduction in QoL score post-COVID-19 infection, as reported by the patients, was approximately 25%, with an overall score of 76.5 ± 26.6 . The main complaints were fatigue, followed by anxiety, dyspnea, depression, and hair loss, all of which significantly impacted their QoL.

5. Discussion

During the past three years of the SARS-COV-2 outbreak worldwide, millions of deaths due to the infection have been reported (15, 16). Aside from its mortality, those who survived the infection were not spared from the long-term devastating effects of this deadly virus. Various studies have assessed QoL at different time intervals post-COVID-19 infection. Some studies evaluated the early continuation of symptoms within a month after the acute phase (17), while others examined the persistence of symptoms and impaired QoL over a longer duration (7). Most of these studies have shown significant impairment in QoL among hospitalized patients after recovery from COVID-19; however, the impact of persistent symptoms on QoL in non-hospitalized patients may have been underestimated. Similar studies in the region have focused on shorter time intervals (1-3 months) post-COVID-19 infection and on different age groups, such as children and adolescents. (18, 19). As evident in the results of this study, impairment of QoL was observed in all categories of assessment six months after recovery from the acute infection. The most significant damage was observed in patients' mental health, with an approximately 30% rise in anxiety and depression six months after recovering from the acute phase of the infection. Deterioration of mental health has been reported in recent meta-analyses inspecting the effects of post-COVID syndrome on QoL (20), and the risk of developing depression in patients, particularly hospitalized patients, has been estimated to be high compared to the normal general population (21). Since almost 58% of the patients experienced hospital admission for their treatment, the increase in anxiety




Figure 1. Flow diagram of the study participants

and depression may be attributed to both the infection itself and the course of treatment (22). Some reasons for increased anxiety and depression during the course of hospital admission and treatment are prolonged admissions, the unfamiliar environment of the hospital, ICU admissions with no visitors allowed, the course of intubation that the patient may not remember, disease stress, long-term high-dose corticosteroid therapy, discharge of the patient with a supplemental oxygen requirement, and the financial burden of admission. As evident in the results, ICU admission, indicative of a more severe disease, was negatively associated with the patient's health status. Stress related to ICU admission has been a poor predictive factor for HRQoL outcomes in various settings (23, 24). Similarly, the socioeconomic status and level of literacy of patients can be influential factors in impaired QoL (25). The majority of the study population had a low level of education and likely low socioeconomic status. Health-related illiteracy toward preventive and therapeutic measures, as well as low-income status, have been found to predict deteriorated QoL (26, 27), although this variable did not significantly impact patients' QoL in this study. Health literacy concerning anxiety and depression has shown beneficial effects in protecting against post-COVID impairment of QoL (28). Additionally, problems in

mobility increased, with a 37% rise in patients reporting some difficulties in walking compared to their condition before the infection. Loss of physical abilities has been reported previously, in line with the results of this study (29). Female gender and older age have been associated with impairment of physical ability and aspects of QoL (17). As shown in the results, female gender and age ≥ 40 years were factors that were associated with impaired health status (P -value < 0.05). In terms of the effect of age on the long-term COVID-19 effects, health impairment in children and younger age has also been studied. Variation in the prevalence of long-term effects of COVID-19 infection in children has been observed, and data are heterogeneous. High rates of fatigue, anosmia, arthralgia, headache, and long-standing dyspnea have been among the most frequent health-related complaints of children after recovering from COVID-19 infection (30, 31). It has been confirmed that comorbid medical conditions and prolonged hospital stays are predictive factors of impaired physical and mental QoL post-COVID-19 infection (32). The highest rate of preexisting medical conditions was diabetes and hypertension, the two major clinical conditions that predispose patients to severe disease and independently predict HRQoL values (24, 26), potentially leading to hospital stay. Although the length

Table 1. General Baseline Characteristics of Patients Enrolled in the Study

Characteristic	Frequency (%)
Gender	
Female	95 (49)
Male	99 (51)
Level of education	
Illiterate or some elementary school degree	71 (36.6)
Middle school to high school diploma	49 (25.3)
Bachelor's degree to master's degree	62 (32)
Doctorate's degree or more	12 (6.2)
Past medical history	
Hypertension	33 (17)
Diabetes	32 (16.5)
Ischemic heart disease	23 (11.9)
Thyroid disorders	8 (4.1)
Asthma/allergy	7 (3.6)
Autoimmune disease	3 (1.5)
Malignancy	4 (2.1)
Type of medication used for COVID-19 infection	
Remdesivir	50 (26)
Favipiravir	50 (26)
Tocilizumab	50 (26)
Pirfenidone	44 (22.9)
Course of COVID infection	
Outpatient	81 (41.8)
Inpatient (ward admission)	86 (44.3)
Inpatient (ICU admission)	27 (13.9)

Abbreviation: ICU; intensive care unit.

of the hospital stay was not recorded in this study, the use of tocilizumab as an anti-inflammatory agent confirms the severity of the disease in 26% of the study population. This confirms the devastating long-term physical and psychological effects of this deadly pandemic, which, despite appearing to have subsided, continues to cause lasting damage. The physical and mental issues associated with COVID-19 must be addressed, considering each nation's beliefs and providing medical and economic support to prevent long-lasting damages to the future well-being of societies. Long-term fatigue has been introduced as a major complication lasting well beyond the acute symptoms (33). Persistent fatigue can significantly contribute to impairments in all QoL categories assessed in this study, including mobility, self-care, usual activities, pain, anxiety, and depression. The overall QoL post-COVID-19 infection has been shown to decline in various studies conducted in different regions with diverse populations (24, 34). This confirms the devastating long-term physical and psychological effects of this deadly pandemic, which, despite

appearing to have subsided, continues to cause lasting damage. The physical and mental issues associated with COVID-19 must be addressed, considering each nation's beliefs and providing medical and economic support to prevent long-lasting damages to the future well-being of societies.

Like any study, this study has limitations. The subjective nature of questionnaire-based studies may introduce variation in the overall report due to differences in each patient's perception of their disabilities. Additionally, due to the profound mental impairment observed post-COVID-19, a significant number of patients allocated at the beginning of the study could not complete the trial and were not included in the final analysis, reducing the total study population. This further supports the severe negative impact of COVID-19 on patients' mental health and QoL. Unfortunately, QoL assessments are mainly based on questionnaires, and the subjective quality of the assessment cannot be overcome, but cross-checking the questionnaire with a close caregiver who has observed

Table 2. Assessment of Health-Related QoL, Pre- and Post-COVID-19 Infection in the Five Categories of Mobility, Self-Care, Usual Activities, Pain/Discomfort and Anxiety/Depression According to EQ-5D-3L Questionnaire

Category of Impairment and Timing	Frequency (%)	Deterioration Rate (%)
Mobility		
I have no problem in walking about		37.7
Pre-infection	193 (99.5)	
Post-infection	120 (61.8)	
I have some problems in walking about		36.1
Pre-infection	0	
Post-infection	70 (36.1)	
I am confined to bed		1.6
Pre-infection	1 (0.5)	
Post-infection	4 (2.1)	
Self-care		
I have no problems in self-care		3.6
Pre-infection	192 (99)	
Post-infection	185 (95.4)	
I have some problems with washing or dressing myself		3.1
Pre-infection	0	
Post-infection	6 (3.1)	
I am unable to wash or dress myself		0.5
Pre-infection	2 (1)	
Post-infection	3 (1.5)	
Usual activities (work, study, housework, ...)		
I have no problems in performing my usual activities		12.9
Pre-infection	192 (99)	
Post-infection	67 (86.1)	
I have some problems with performing my usual activities		11.9
Pre-infection	1 (0.5)	
Post-infection	24 (12.4)	
I am unable to perform my usual activities		1
Pre-infection	1 (0.5)	
Post-infection	3 (1.5)	
Pain/discomfort		
I have no pain or discomfort		10.8
Pre-infection	188 (96.9)	
Post-infection	167 (86.1)	
I have moderate pain or discomfort		10.3
Pre-infection	4 (2.1)	
Post-infection	24 (12.4)	
I have extreme pain or discomfort		0.5
Pre-infection	2 (1)	
Post-infection	3 (1.5)	
Anxiety/depression		
I am not anxious or depressed		42.2
Pre-infection	190 (97.9)	
Post-infection	108 (55.7)	
I am moderately anxious or depressed		33.5
Pre-infection	4 (2.1)	
Post-infection	69 (35.6)	
I am extremely anxious or depressed		8.8
Pre-infection	0	
Post-infection	17 (8.8)	

the patient’s impairments during the infection and after recovery can be a suggestion that may improve the reliability of answers given to each question by the patient himself. This method may also be applied if profound mental impairment leads to patient loss during the study.

5.1. Conclusions

Impairment in QoL, physical and mental abilities of patients after COVID-19 infection was evident. Female gender, age ≥ 40 years, and ICU admission were independently associated with impairment of QoL.

Impairments in QoL post-COVID-19 must be detected and addressed in different societies with diverse social, economic, and healthcare settings to mitigate the further damage to the well-being of populations. Prompt investigation and detection of the population with impairments in HRQoL is mandatory for developing health policies, including free-of-charge rehab and counseling sessions to prevent further damage and economic burden to societies and their healthcare systems.

Acknowledgements

Table 3. Mean Scoring of Pre- and Post-COVID-19 Infection Assessment of Quality of Life According to Patients' Quality of Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression^{a,b}

Category of Impairment	Score		P-Value
	Pre-COVID Infection	Post-COVID Infection	
Mobility	1 ± 0.2	1.49 ± 0.5	< 0.001
Self-care	1.02 ± 0.9	1.06 ± 1	0.01
Usual activities	1.01 ± 0.5	1.15 ± 0.6	< 0.001
Pain/discomfort	1.03 ± 0.6	1.15 ± 0.7	< 0.001
Anxiety/depression	1.02 ± 0.3	1.5 ± 0.5	< 0.001

^a Values are presented as mean ± SD.

^b Kruskal-Wallis one-way analysis of variance.

Table 4. Multivariable Regression Analysis for Factors Associated with Worsening of Health Status Six Months Following the Infection (n = 194)

Factors Affecting Health Status	Odds Ratio (95% CI)	P-Value
Age (ref: < 40 y)	2.72 (1.54-3.38)	0.025
≥ 40		
< 40		
Gender (ref: Male)	2.64 (1.76-6.14)	0.005
Level of education (ref: Elementary school degree)	0.87 (0.62-1.76)	0.598
Past medical history (ref: No)	1.34 (0.82-2.92)	0.355
ICU admission (ref: No)	2.22 (1.14-4.32)	0.019

Abbreviations: ICU; intensive care unit, CI, confidence interval; ref, reference category.

The results of this study is derived from the PharmD thesis of Ms. M K and the project has been financially supported by Research Council of Shiraz University of Medical Sciences, Shiraz, Iran.

Footnotes

Authors' Contribution: All authors fulfill authorship criteria. D. F., L. M. and R. N. contributed in developing the idea and design and methodology of the work. M. K. M. performed the investigation and collected the data. Analysis was performed by L. M., D. F., R. N. and M. K. M.; D. F. and L. M. contributed in writing and revising the final draft. Project supervision was performed by L. M. and D. F.

Conflict of Interests Statement: The authors declare no conflicts of interest.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: This study was approved under the ethics approval code (IR.SUMS.REC.1399.1007).

Funding/Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Informed Consent: Informed consent was obtained from all individual participants included in the study.

References

- Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *Cochrane Database Syst Rev.* 2020;7(7). CD013665. [PubMed ID: 32633856]. [PubMed Central ID: PMC7386785]. <https://doi.org/10.1002/14651858.CD013665>.
- Lima CMADO. Information about the new coronavirus disease (COVID-19). *Radiologia Brasileira.* 2020;53(2):V-VI. <https://doi.org/10.1590/0100-3984.2020.53.2e1>.
- Group TW. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. *Soc Sci Med.* 1998;46(12):1569-85. [PubMed ID: 9672396]. [https://doi.org/10.1016/S0277-9536\(98\)00009-4](https://doi.org/10.1016/S0277-9536(98)00009-4).
- Zhang Y, Ma ZF. Impact of the COVID-19 Pandemic on Mental Health and Quality of Life among Local Residents in Liaoning Province, China: A Cross-Sectional Study. *Int J Environ Res Public Health.* 2020;17(7). [PubMed ID: 32244498]. [PubMed Central ID: PMC7177660]. <https://doi.org/10.3390/ijerph17072381>.

5. Qi M, Li P, Moyle W, Weeks B, Jones C. Physical Activity, Health-Related Quality of Life, and Stress among the Chinese Adult Population during the COVID-19 Pandemic. *Int J Environ Res Public Health*. 2020;**17**(18). [PubMed ID: 32906604]. [PubMed Central ID: PMC7558071]. <https://doi.org/10.3390/ijerph17186494>.
6. Epifanio MS, Andrei F, Mancini G, Agostini F, Piombo MA, Spicuzza V, et al. The Impact of COVID-19 Pandemic and Lockdown Measures on Quality of Life among Italian General Population. *J Clin Med*. 2021;**10**(2). [PubMed ID: 33466778]. [PubMed Central ID: PMC7830623]. <https://doi.org/10.3390/jcm10020289>.
7. Carfi A, Bernabei R, Landi F; Gemelli Against Covid-Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020;**324**(6):603-5. [PubMed ID: 32644129]. [PubMed Central ID: PMC7349096]. <https://doi.org/10.1001/jama.2020.12603>.
8. Alinia C, Yaghmaei S, Abdullah FZ, Ahmadi A, Samadi N, Pourteimour S, et al. The health-related quality of life in Iranian patients with COVID-19. *BMC Infect Dis*. 2021;**21**(1):459. [PubMed ID: 34016041]. [PubMed Central ID: PMC8135385]. <https://doi.org/10.1186/s12879-021-06170-z>.
9. Saffari M, Sanaeinasab H, Rashidi-Jahan H, Hajiagha AP, Mahmoudi H, Al-Zaben F, et al. Determinants of health-related quality of life in Iranian patients after recovery from COVID-19: demographic influences and insomnia. *Int J Public Health Sci (IJPHS)*. 2022;**11**(1). <https://doi.org/10.11591/ijphs.v11i1.21039>.
10. Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. *Med J Aust*. 2020;**213**(2):54-56. [PubMed ID: 32572965]. [PubMed Central ID: PMC7361309]. <https://doi.org/10.5694/mja2.50674>.
11. Alipour S, Mahmoudi L, Ahmadi F. Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19. *Drug Deliv Transl Res*. 2023;**13**(3):705-15. [PubMed ID: 36260223]. [PubMed Central ID: PMC9580423]. <https://doi.org/10.1007/s13346-022-01251-1>.
12. England NHS. *After-care needs of inpatients recovering from COVID-19*. NHS England; 2020. Available from: <https://www.pcrs-uk.org/sites/default/files/nhs-aftercarecovid.pdf>.
13. Baig AM. Neurological manifestations in COVID-19 caused by SARS-CoV-2. *CNS Neurosci Ther*. 2020;**26**(5):499-501. [PubMed ID: 32266761]. [PubMed Central ID: PMC7163592]. <https://doi.org/10.1111/cns.13372>.
14. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solis-Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. *Pulmonol*. 2021;**27**(4):328-37. [PubMed ID: 33262076]. [PubMed Central ID: PMC7687368]. <https://doi.org/10.1016/j.pulmoe.2020.10.013>.
15. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. *Lancet Infect Dis*. 2020;**20**(7):773. [PubMed ID: 32171390]. [PubMed Central ID: PMC7118515]. [https://doi.org/10.1016/S1473-3099\(20\)30195-X](https://doi.org/10.1016/S1473-3099(20)30195-X).
16. Bryson WJ. Long-term health-related quality of life concerns related to the COVID-19 pandemic: a call to action. *Qual Life Res*. 2021;**30**(3):643-5. [PubMed ID: 33073307]. [PubMed Central ID: PMC7568937]. <https://doi.org/10.1007/s11136-020-02677-1>.
17. Chen KY, Li T, Gong FH, Zhang JS, Li XK. Predictors of Health-Related Quality of Life and Influencing Factors for COVID-19 Patients, a Follow-Up at One Month. *Front Psychiatry*. 2020;**11**:668. [PubMed ID: 32733299]. [PubMed Central ID: PMC7360857]. <https://doi.org/10.3389/fpsy.2020.00668>.
18. Saberian P, Pazooki B, Hasani-Sharamin P, Garjani K, Ahmadi Hatam Z, Dadashi F, et al. Persistent/Late-Onset Complications of COVID-19 in General Population: A Cross-Sectional Study in Tehran, Iran. *Int J Community Based Nurs Midwifery*. 2022;**10**(3):234-45. [PubMed ID: 35855388]. [PubMed Central ID: PMC9287568]. <https://doi.org/10.30476/IJCBNM.2022.93302.1917>.
19. Asadi-Pooya AA, Nemat H, Shahisavandi M, Akbari A, Emami A, Lotfi M, et al. Long COVID in children and adolescents. *World J Pediatr*. 2021;**17**(5):495-9. [PubMed ID: 34478045]. [PubMed Central ID: PMC8414448]. <https://doi.org/10.1007/s12519-021-00457-6>.
20. Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. *J Med Virol*. 2022;**94**(1):253-62. [PubMed ID: 34463956]. [PubMed Central ID: PMC8662132]. <https://doi.org/10.1002/jmv.27309>.
21. Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment. *CNS Drugs*. 2022;**36**(7):681-702. [PubMed ID: 35727534]. [PubMed Central ID: PMC9210800]. <https://doi.org/10.1007/s40263-022-00931-3>.
22. Firoozabadi D, Kheshti F, Abdollahifard S, Taherifard E, Kheshti MR. The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis. *Health Sci Rep*. 2022;**5**(6):e892. [PubMed ID: 36268458]. [PubMed Central ID: PMC9577115]. <https://doi.org/10.1002/hsr2.892>.
23. Fradelos EC, Boutlas S, Tsimitrea E, Sistou A, Tourlakopoulos K, Papanthanasidou IV, et al. Perceived Symptoms, Mental Health and Quality of Life after Hospitalization in COVID-19 Patients. *J Pers Med*. 2022;**12**(5). [PubMed ID: 35629149]. [PubMed Central ID: PMC9147638]. <https://doi.org/10.3390/jpm12050728>.
24. Figueiredo EAB, Silva WT, Tsopanoglou SP, Vitorino DFM, Oliveira LFL, Silva KLS, et al. The health-related quality of life in patients with post-COVID-19 after hospitalization: a systematic review. *Rev Soc Bras Med Trop*. 2022;**55**:e0741. [PubMed ID: 35352761]. [PubMed Central ID: PMC9053755]. <https://doi.org/10.1590/0037-8682-0741-2021>.
25. Zhang Q. The cost of illiteracy: A causal inference study on how illiteracy affects physical and mental health. *Health Education Journal*. 2020;**80**(1):54-66. <https://doi.org/10.1177/0017896920949894>.
26. Arab-Zozani M, Hashemi F, Safari H, Yousefi M, Ameri H. Health-Related Quality of Life and its Associated Factors in COVID-19 Patients. *Osong Public Health Res Perspect*. 2020;**11**(5):296-302. [PubMed ID: 33117634]. [PubMed Central ID: PMC7577388]. <https://doi.org/10.24171/j.phrp.2020.11.5.05>.
27. Poudel AN, Zhu S, Cooper N, Roderick P, Alwan N, Tarrant C, et al. Impact of Covid-19 on health-related quality of life of patients: A structured review. *PLoS One*. 2021;**16**(10):e0259164. [PubMed ID: 34710173]. [PubMed Central ID: PMC8553121]. <https://doi.org/10.1371/journal.pone.0259164>.
28. Tran TV, Nguyen HC, Pham LV, Nguyen MH, Nguyen HC, Ha TH, et al. Impacts and interactions of COVID-19 response involvement, health-related behaviours, health literacy on anxiety, depression and health-related quality of life among healthcare workers: a cross-sectional study. *BMJ Open*. 2020;**10**(12):e041394. [PubMed ID: 33293320]. [PubMed Central ID: PMC7722826]. <https://doi.org/10.1136/bmjopen-2020-041394>.
29. Park KH, Kim AR, Yang MA, Lim SJ, Park JH. Impact of the COVID-19 pandemic on the lifestyle, mental health, and quality of life of adults in South Korea. *PLoS One*. 2021;**16**(2):e0247970. [PubMed ID: 33635897]. [PubMed Central ID: PMC7909697]. <https://doi.org/10.1371/journal.pone.0247970>.

30. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. *Sci Rep.* 2022;**12**(1):9950. [PubMed ID: 35739136]. [PubMed Central ID: PMC9226045]. <https://doi.org/10.1038/s41598-022-13495-5>.
31. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. *Eur J Pediatr.* 2022;**181**(12):3995-4009. [PubMed ID: 36107254]. [PubMed Central ID: PMC9476461]. <https://doi.org/10.1007/s00431-022-04600-x>.
32. Umbrello M, Miori S, Sanna A, Lassola S, Baruzzo E, Penzo D, et al. High rates of impaired quality of life and social and economic problems at 6 months after COVID-19-related ARDS. *J Anesth Analg Crit Care.* 2022;**2**(1):20. [PubMed ID: 37386529]. [PubMed Central ID: PMC9109430]. <https://doi.org/10.1186/s44158-022-00048-5>.
33. Miyazato Y, Tsuzuki S, Morioka S, Terda M, Kutsuna S, Saito S, et al. Risk factors associated with development and persistence of long COVID. *Medrxiv.* 2021;**Preprint**. <https://doi.org/10.1101/2021.09.22.21263998>.
34. de Oliveira Almeida K, Nogueira Alves IG, de Queiroz RS, de Castro MR, Gomes VA, Santos Fontoura FC, et al. A systematic review on physical function, activities of daily living and health-related quality of life in COVID-19 survivors. *Chronic Illn.* 2023;**19**(2):279-303. [PubMed ID: 35404175]. [PubMed Central ID: PMC9006095]. <https://doi.org/10.1177/17423953221089309>.